Breaking News, Collaborations & Alliances

Merck, Hanwha To Develop Enbrel Biosimilar

Merck and Hanwha Chemical Corp. have entered into an exclusive global agreement to develop and commercialize HD203, Hanwha’s biosimilar form of Enbrel. Hanwha, through its Bio Business Unit, and Merck, through a subsidiary, will work to develop and commercialize HD203.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck and Hanwha Chemical Corp. have entered into an exclusive global agreement to develop and commercialize HD203, Hanwha’s biosimilar form of Enbrel. Hanwha, through its Bio Business Unit, and Merck, through a subsidiary, will work to develop and commercialize HD203. Merck will conduct clinical development and will be responsible for manufacturing. Upon marketing approval, Merck will commercialize HD203 globally, except for in Korea and Turkey, where Hanwha retains marketing rights. Financial ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters